Genome-wide association analyses of ovarian cancer patients undergoing primary debulking surgery identify candidate genes for residual disease.
Journal
NPJ genomic medicine
ISSN: 2056-7944
Titre abrégé: NPJ Genom Med
Pays: England
ID NLM: 101685193
Informations de publication
Date de publication:
05 Mar 2024
05 Mar 2024
Historique:
received:
14
06
2023
accepted:
15
01
2024
medline:
6
3
2024
pubmed:
6
3
2024
entrez:
5
3
2024
Statut:
epublish
Résumé
Survival from ovarian cancer depends on the resection status after primary surgery. We performed genome-wide association analyses for resection status of 7705 ovarian cancer patients, including 4954 with high-grade serous carcinoma (HGSOC), to identify variants associated with residual disease. The most significant association with resection status was observed for rs72845444, upstream of MGMT, in HGSOC (p = 3.9 × 10
Identifiants
pubmed: 38443389
doi: 10.1038/s41525-024-00395-y
pii: 10.1038/s41525-024-00395-y
doi:
Types de publication
Journal Article
Langues
eng
Pagination
19Subventions
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : D0761/15-1
Investigateurs
David Bowtell
(D)
Sian Fereday
(S)
Nadia Traficante
(N)
Jillian Hung
(J)
Michael Friedlander
(M)
Andreas Obermair
(A)
Peter Grant
(P)
Vanessa Beesley
(V)
Penelope Blomfield
(P)
Alison Brand
(A)
Alison Davis
(A)
Yee Leung
(Y)
James Nicklin
(J)
Michael Quinn
(M)
Karen Livingstone
(K)
Helen O'Neill
(H)
Merran Williams
(M)
Informations de copyright
© 2024. The Author(s).
Références
Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 70, 7–30 (2020).
pubmed: 31912902
doi: 10.3322/caac.21590
Jelovac, D. & Armstrong, D. K. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J. Clin. 61, 183–203 (2011).
pubmed: 21521830
pmcid: 3576854
doi: 10.3322/caac.20113
Freimund, A. E., Beach, J. A., Christie, E. L. & Bowtell, D. D. L. Mechanisms of drug resistance in high-grade serous ovarian cancer. Hematol. Oncol. Clin. North Am. 32, 983–996 (2018).
pubmed: 30390769
doi: 10.1016/j.hoc.2018.07.007
Rochon, J. & du Bois, A. Clinical research in epithelial ovarian cancer and patients’ outcome. Ann. Oncol. 22, vii16–vii19 (2011).
pubmed: 22039139
doi: 10.1093/annonc/mdr421
Tseng, J. H. et al. Continuous improvement in primary Debulking surgery for advanced ovarian cancer: do increased complete gross resection rates independently lead to increased progression-free and overall survival? Gynecol. Oncol. 151, 24–31 (2018).
pubmed: 30126704
pmcid: 6247423
doi: 10.1016/j.ygyno.2018.08.014
Norppa, N., Staff, S., Helminen, M., Auranen, A. & Saarelainen, S. Improved survival after implementation of ultra-radical surgery in advanced epithelial ovarian cancer: Results from a tertiary referral center. Gynecol. Oncol. 165, 478–485 (2022).
pubmed: 35397919
doi: 10.1016/j.ygyno.2022.03.023
Chang, S.-J. & Bristow, R. E. Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: Redefining ‘optimal’ residual disease. Gynecol. Oncol. 125, 483–492 (2012).
pubmed: 22366151
doi: 10.1016/j.ygyno.2012.02.024
du Bois, A. et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. Cancer 115, 1234–1244 (2009).
pubmed: 19189349
doi: 10.1002/cncr.24149
Kommoss, S. et al. Prognostic impact of additional extended surgical procedures in advanced-stage primary ovarian cancer. Ann. Surg. Oncol. 17, 279–286 (2010).
pubmed: 19898901
doi: 10.1245/s10434-009-0787-8
Eisenhauer, E. L. et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC–IV epithelial ovarian cancer. Gynecol. Oncol. 103, 1083–1090 (2006).
pubmed: 16890277
doi: 10.1016/j.ygyno.2006.06.028
Chi, D. S. et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol. Oncol. 114, 26–31 (2009).
pubmed: 19395008
doi: 10.1016/j.ygyno.2009.03.018
Harter, P. et al. Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer. Gynecol. Oncol. 121, 615–619 (2011).
pubmed: 21414656
doi: 10.1016/j.ygyno.2011.02.014
Manning-Geist, B. L. et al. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome. Am. J. Obstet. Gynecol. 221, 326.e1–326.e7 (2019).
pubmed: 31082382
doi: 10.1016/j.ajog.2019.05.006
Heitz, F. et al. Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery. Gynecol. Oncol. 141, 264–270 (2016).
pubmed: 26975900
doi: 10.1016/j.ygyno.2016.03.015
Riester, M. et al. Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. JNCI J. Natl Cancer Inst. 106, 1–12 (2014).
doi: 10.1093/jnci/dju048
Liu, Z. et al. Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation. Gynecol. Oncol. 139, 394–400 (2015).
pubmed: 26348314
pmcid: 4679504
doi: 10.1016/j.ygyno.2015.08.026
Kenny, H. A. et al. Mesothelial cells promote early Ovarian cancer metastasis through fibronectin secretion. J. Clin. Investig. 124, 4614–4628 (2014).
pubmed: 25202979
pmcid: 4191043
doi: 10.1172/JCI74778
Brieger, K. K. et al. Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. Gynecol. Oncol. 158, 702–709 (2020).
pubmed: 32641237
pmcid: 7487048
doi: 10.1016/j.ygyno.2020.06.481
Phelan, C. M. et al. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat. Genet. 49, 680–691 (2017).
pubmed: 28346442
pmcid: 5612337
doi: 10.1038/ng.3826
Heitz, F. et al. Dilution of molecular-pathologic gene signatures by medically associated factors might prevent prediction of resection status after debulking surgery in patients with advanced ovarian cancer. Clin. Cancer Res. 26, 213–219 (2020).
pubmed: 31527166
doi: 10.1158/1078-0432.CCR-19-1741
Kommoss, S. et al. Bevacizumab may differentially improve ovarian cancer outcome in patients with proliferative and mesenchymal molecular subtypes. Clin. Cancer Res. 23, 3794–3801 (2017).
pubmed: 28159814
pmcid: 5661884
doi: 10.1158/1078-0432.CCR-16-2196
Glubb, D. M. et al. Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. Oncotarget 8, 64670–64684 (2017).
pubmed: 29029385
pmcid: 5630285
doi: 10.18632/oncotarget.18501
Talhouk, A. et al. Development and validation of the gene expression predictor of high-grade serous ovarian carcinoma molecular SubTYPE (PrOTYPE). Clin. Cancer Res. 26, 5411–5423 (2020).
pubmed: 32554541
pmcid: 7572656
doi: 10.1158/1078-0432.CCR-20-0103
Quinn, M. C. J. et al. Identification of a locus near ULK1 associated with progression-free survival in ovarian cancer. Cancer Epidemiol. Biomark. Prev. 30, 1669–1680 (2021).
doi: 10.1158/1055-9965.EPI-20-1817
Bonome, T. et al. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res. 68, 5478–5486 (2008).
pubmed: 18593951
pmcid: 7039050
doi: 10.1158/0008-5472.CAN-07-6595
Tucker, S. L. et al. Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer. Clin. Cancer Res. 20, 3280–3288 (2014).
pubmed: 24756370
pmcid: 4062703
doi: 10.1158/1078-0432.CCR-14-0445
Berchuck, A. et al. Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Am. J. Obstet. Gynecol. 190, 910–923 (2004).
pubmed: 15118612
doi: 10.1016/j.ajog.2004.02.005
Borley, J., Wilhelm-Benartzi, C., Brown, R. & Ghaem-Maghami, S. Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? A systematic literature review. Br. J. Cancer 107, 1069–1074 (2012).
pubmed: 22935582
pmcid: 3461167
doi: 10.1038/bjc.2012.376
Kim, S. R. et al. Maximizing cancer prevention through genetic navigation for Lynch syndrome detection in women with newly diagnosed endometrial and nonserous/nonmucinous epithelial ovarian cancer. Cancer 127, 3082–3091 (2021).
pubmed: 33983630
doi: 10.1002/cncr.33625
Ataseven, B. et al. Clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1/2-mutation—real life data. Gynecol. Oncol. 163, 569–577 (2021).
pubmed: 34565600
doi: 10.1016/j.ygyno.2021.09.004
Hegi, M. E. et al. Clinical trial substantiates the predictive value of O-6-Methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin. Cancer Res. 10, 1871–1874 (2004).
pubmed: 15041700
doi: 10.1158/1078-0432.CCR-03-0384
Della Monica, R. et al. MGMT and whole‐genome DNA methylation impacts on diagnosis, prognosis and therapy of glioblastoma multiforme. Int. J. Mol. Sci. 23, 7148 (2022).
pubmed: 35806153
pmcid: 9266959
doi: 10.3390/ijms23137148
Gessler, F. et al. Surgery for glioblastoma in light of molecular markers: impact of resection and MGMT promoter methylation in newly diagnosed IDH-1 wild-type glioblastomas. Neurosurgery 84, 190–197 (2019).
pubmed: 29617848
doi: 10.1093/neuros/nyy049
Incekara, F. et al. The association between the extent of glioblastoma resection and survival in light of MGMT promoter methylation in 326 patients with newly diagnosed IDH-wildtype glioblastoma. Front. Oncol. 10, 1–8 (2020).
Shouse, G. P., Nobumori, Y., Panowicz, M. J. & Liu, X. ATM-mediated phosphorylation activates the tumor-suppressive function of B56γ–PP2A. Oncogene 30, 3755–3765 (2011).
pubmed: 21460856
doi: 10.1038/onc.2011.95
Ambjørn, S. M. et al. A complex of BRCA2 and PP2A-B56 is required for DNA repair by homologous recombination. Nat. Commun. 12, 5748 (2021).
pubmed: 34593815
pmcid: 8484605
doi: 10.1038/s41467-021-26079-0
Perrotti, D. & Neviani, P. Protein phosphatase 2A: a target for anticancer therapy. Lancet Oncol. 14, e229–e238 (2013).
pubmed: 23639323
pmcid: 3913484
doi: 10.1016/S1470-2045(12)70558-2
Ruvolo, P. P. The broken “Off” switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance. BBA Clin. 6, 87–99 (2016).
pubmed: 27556014
pmcid: 4986044
doi: 10.1016/j.bbacli.2016.08.002
Avelar, R. A. et al. Small molecule-mediated stabilization of PP2A modulates the Homologous Recombination pathway and potentiates DNA damage-induced cell death. Mol. Cancer Ther. https://doi.org/10.1158/1535-7163.MCT-21-0880 (2023).
Perren, T. J. et al. A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 365, 2484–2496 (2011).
pubmed: 22204725
doi: 10.1056/NEJMoa1103799
Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumors. J. Natl Cancer Inst. 92, 205–216 (2000).
pubmed: 10655437
doi: 10.1093/jnci/92.3.205
D. Turner, S. qqman: an R package for visualizing GWAS results using Q-Q and Manhattan plots. J. Open Source Softw. 3, 731 (2018).
doi: 10.21105/joss.00731
Zhao, J. H. Gap: genetic analysis package. J. Stat. Softw. 23, 1–18 (2007).
doi: 10.18637/jss.v023.i08
Watanabe, K., Taskesen, E., Van Bochoven, A. & Posthuma, D. Functional mapping and annotation of genetic associations with FUMA. Nat. Commun. 8, 1–10 (2017).
doi: 10.1038/s41467-017-01261-5
de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: generalized gene-set analysis of GWAS data. PLoS Comput. Biol. 11, 1–19 (2015).
doi: 10.1371/journal.pcbi.1004219
Arnold, M., Raffler, J., Pfeufer, A., Suhre, K. & Kastenmüller, G. SNiPA: An interactive, genetic variant-centered annotation browser. Bioinformatics 31, 1334–1336 (2015).
pubmed: 25431330
doi: 10.1093/bioinformatics/btu779
Lánczky, A. & Győrffy, B. Web-based survival analysis tool tailored for medical research (KMplot): development and implementation. J. Med. Internet Res. 23, e27633 (2021).
pubmed: 34309564
pmcid: 8367126
doi: 10.2196/27633